Peripheral Artery Disease - 5EU China Drug Forecast and Market Analysis to 2024
"Peripheral
Artery Disease - 5EU China Drug Forecast and Market Analysis to
2024".
The Report covers current Market Trends, Analysis, Forecast, Review,
Share, Size, Growth, Effect.
Description-
Summary
In
the 2014 base year, the global PAD
market was worth approximately $543.4m, including both branded and
generic drugs. By 2024, GlobalData expects that the global PAD market
will experience significant expansion, with a Compound Annual Growth
Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The
dramatic increase in the value of the overall global PAD therapeutics
market will be partly attributable to the launch of several PAD drugs
currently in late-stage pipeline development, which GlobalData
believes have extraordinary potential. These include the novel
antithrombotic pharmacological agents, Merck & Co.s Zontivity
(vorapaxar), AstraZenecas Brilinta (ticagrelor), and Bayer and
Janssens (a subsidiary of Johnson & Johnson) Xarelto
(rivaroxaban), which have the capacity to reform the antiplatelet and
anticoagulatory PAD treatment landscape.
Total
5EU sales for the PAD therapeutics market in 2014 was approximately
$198.8m. By 2024, sales of drugs that are used to relieve the
symptoms of PAD will decline quite dramatically. This group of
medicines will only contribute approximately 5% to total 5EU PAD
sales by the end of the forecast period.
*This
is an on-demand report and will be delivered within 24 hrs.
(excluding weekends) of the purchase.
Scope
-
Overview of PAD including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
-
Detailed information on the key drugs in 5EU including product
PADcription, safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in 5EU from 2014-2024.
-
Analysis of the impact of key events as well the drivers and
restraints affecting 5EU PAD market.
Reasons
to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for PAD.
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2014-2024 in 5EU.
For
More Information Kindly Contact:
ResearchMoz
Global Pvt. Ltd.
90
State Street,
Albany,
NY 12207,
United
States
Blog
- http://bit.ly/2b1Ayn6
866-997-4948
(Us-Canada Toll Free),
+1-518-621-2074,
Email
to:
sales@researchmoz.us,
Comments
Post a Comment